Govind Babu

Dr. Govind Babu

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ABAjay Balakrishnan
Ajay Balakrishnan
DKDeepak Koppaka
Deepak Koppaka
AAAbhishek Anand
Abhishek Anand
BDBarnali Deb
Barnali Deb
GGGianluca Grenci
Gianluca Grenci
PKPrashant Kumar
Prashant Kumar
Circulating tumor cells (CTCs) are putative markers of tumor prognosis and may serve to evaluate patient’s response to chemotherapy. CTCs are often detected as single cells but infrequently as clusters and are indicative of worse prognosis. In this study, we developed a short-term culture of nucleated blood cells which was applied to blood samples from breast, lung, esophageal and bladder cancer patients. Clusters of different degrees of compactness, classified as very tight, tight and loose were observed across various cancer types. These clusters show variable expression of cytokeratins. Cluster formation from blood samples obtained during the course of chemotherapy was found to be associated with disease progression and shorter overall survival. The short-term cultures offer a robust and highly reliable method for early prediction of treatment response in different cancer types.

16 September 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TDTamasa De
Tamasa De
SGShina Goyal
Shina Goyal
GBGowri Balachander
Gowri Balachander
KCKaushik Chatterjee
Kaushik Chatterjee
PKPrashant Kumar
Prashant Kumar
ARAnu Rangarajan
Anu Rangarajan
The majority of the cancer-associated deaths is due to metastasis—the spread of tumors to other organs. Circulating tumor cells (CTCs), which are shed from the primary tumor into the circulation, serve as precursors of metastasis. CTCs have now gained much attention as a new prognostic and diagnostic marker, as well as a screening tool for patients with metastatic disease. However, very little is known about the biology of CTCs in cancer metastasis. An increased understanding of CTC biology, their heterogeneity, and interaction with other cells can help towards a better understanding of the metastatic process, as well as identify novel drug targets. Here we present a novel ex vivo 3D system for culturing CTCs from breast cancer patient blood samples using porous poly(ε-caprolactone) (PCL) scaffolds. As a proof of principle study, we show that ex vivo culture of 12/16 (75%) advanced stage breast cancer patient blood samples were enriched for CTCs identified as CK+ (cytokeratin positive) and CD45− (CD45 negative) cells. The deposition of extracellular matrix proteins on the PCL scaffolds permitted cellular attachment to these scaffolds. Detection of Ki-67 and bromodeoxyuridine (BrdU) positive cells revealed proliferating cell population in the 3D scaffolds. The CTCs cultured without prior enrichment exhibited dynamic differences in epithelial (E) and mesenchymal (M) composition. Thus, our 3D PCL scaffold system offers a physiologically relevant model to be used for studying CTC biology as well as for individualized testing of drug susceptibility. Further studies are warranted for longitudinal monitoring of epithelial–mesenchymal transition (EMT) in CTCs for clinical association.

1 December 2011 in Indian Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SPSamit Purohit
Samit Purohit
RBRohan Bhise
Rohan Bhise
SASandhya Appachu
Sandhya Appachu
KLK. C. Lakshmaiah
K. C. Lakshmaiah
GBGovind Babu
Govind Babu


19 July 2013 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
GBGovind Babu
Govind Babu
Kidwai Memorial Institute of Bangalore is one of the most comprehensive and major regional cancer center. It was established in 1974 and caters population not only from Karnataka, but also from Tamil Nadu, Andhra Pradesh. They presented the data of 540 patients out of which 95% patients were in chronic phase. Complete hematological response was seen in 98.45 of patients. Overall survival at 5 years was 86.5%.101 patients has suboptimal response were considered for and underwent mutational analysis, out of which 27 patients showed various mutations and are mentioned elaborately in the article.

1 December 2012 in Indian Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SPSamit Purohit
Samit Purohit
RBRohan Bhise
Rohan Bhise
DLD. Lokanatha
D. Lokanatha
GBGovind Babu
Govind Babu